相关论文: MAGIC: Multi-scale Heterogeneity Analysis and Clus…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, structural brain changes, and genetic predispositions. This study leverages machine-learning and statistical techniques to investigate…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that severely impairs cognitive function and quality of life. Timely intervention in AD relies heavily on early and precise diagnosis, which remains challenging due to the…
Reliable Alzheimer's disease (AD) diagnosis increasingly relies on multimodal assessments combining structural Magnetic Resonance Imaging (MRI) and Electronic Health Records (EHR). However, deploying these models is bottlenecked by modality…
The imaging community has increasingly adopted machine learning (ML) methods to provide individualized imaging signatures related to disease diagnosis, prognosis, and response to treatment. Clinical neuroscience and cancer imaging have been…
Alzheimers Disease (AD) is a progressive neurodegenerative disorder that poses significant challenges in its early diagnosis, often leading to delayed treatment and poorer outcomes for patients. Traditional diagnostic methods, typically…
Alzheimer's Disease (AD) is one of the most concerned neurodegenerative diseases. In the last decade, studies on AD diagnosis attached great significance to artificial intelligence (AI)-based diagnostic algorithms. Among the diverse…
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease; yet its currently available treatments are limited to stopping disease progression. Moreover, effectiveness of these treatments is not guaranteed due to the…
Unsupervised learning can discover various unseen abnormalities, relying on large-scale unannotated medical images of healthy subjects. Towards this, unsupervised methods reconstruct a 2D/3D single medical image to detect outliers either in…
Alzheimer's Disease (AD) is the most common neurodegenerative disorder with one of the most complex pathogeneses, making effective and clinically actionable decision support difficult. The objective of this study was to develop a novel…
Alzheimer's Disease (AD) is a progressive neurodegenerative disease. Amnestic mild cognitive impairment (MCI) is a common first symptom before the conversion to clinical impairment where the individual becomes unable to perform activities…
Wearable sensor technologies and deep learning are transforming healthcare management. Yet, most health sensing studies focus narrowly on physical chronic diseases. This overlooks the critical need for joint assessment of comorbid physical…
Alzheimer's disease (AD) exhibits substantial clinical and biological heterogeneity, complicating efforts in treatment and intervention development. While new computational methods offer insights into AD progression, the reproducibility of…
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of…
Alzheimer's disease (AD) progression follows a complex continuum from normal cognition (NC) through mild cognitive impairment (MCI) to dementia, yet most deep learning approaches oversimplify this into discrete classification tasks. This…
Recent evidence has shown that structural magnetic resonance imaging (MRI) is an effective tool for Alzheimer's disease (AD) prediction and diagnosis. While traditional MRI-based diagnosis uses images acquired at a single time point, a…
Alzheimer's Disease (AD) is the most widespread neurodegenerative disease, affecting over 50 million people across the world. While its progression cannot be stopped, early and accurate diagnostic testing can drastically improve quality of…
Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disease which destroys brain cells and causes loss to patient's memory. An early detection can prevent the patient from further damage of the brain cells and hence…
The aging population of the U.S. drives the prevalence of Alzheimer's disease. Brookmeyer et al. forecasts approximately 15 million Americans will have either clinical AD or mild cognitive impairment by 2060. In response to this urgent…
Alzheimer s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, where early detection is essential for timely intervention and improved patient outcomes. Traditional diagnostic methods are…
Mild cognitive impairment (MCI) is the prodromal stage of Alzheimer's disease (AD) and thus enrolling MCI subjects to undergo clinical trials is worthwhile. However, MCI groups usually show significant diversity and heterogeneity in the…